Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

Phase 2 Completed 16 enrolled Marc L Gordon, MD Janssen Scientific Affairs, LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, pilot study designed to explore whether daratumumab may have a clinically meaningful effect in patients with mild to moderate Alzheimer's disease.

Timeline

Start: 2019-11-06
Primary completion: 2023-06-08
Completion: 2023-08-15

Publications

Zhang SQ, Lee J, Pan JP, Enger R, Hrubos-Strom H, Musiek ES, Fang EF, Le W. NAD+-circadian rhythm coupling in dementia. Alzheimers Dement. 2026 May;22(5):e71360. doi: 10.1002/alz.71360.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Daratumumab	Monoclonal antibody	1800 mg	Subcutaneous
Background	rHuPH20	Protein / enzyme biologic	30000 iu	Subcutaneous

Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

Summary

Timeline

Publications

Drugs

Indications